RHÖN-KLINIKUM Aktiengesellschaft: The Board of Management of RHÖN-KLINIKUM AG considers timely agreement with the State of Hesse on granting subsidies to UKGM to be questionable
May 08, 2022 at 08:24 pm
Share
DGAP-Ad-hoc: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Letter of Intent
RHÖN-KLINIKUM Aktiengesellschaft: The Board of Management of RHÖN-KLINIKUM AG considers timely agreement with the State of Hesse on granting subsidies to UKGM to be questionable
09-May-2022 / 02:22 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The Board of Management of RHÖN-KLINIKUM AG today assessed the currently ongoing negotiations with the State of Hesse on a follow-up agreement regarding the granting of investment subsidies for the Universitätsklinikum Gießen und Marburg GmbH (UKGM) and corresponding obligations of the company. It is to replace the existing agreement. In view of the course of negotiations to date, the Board of Management concluded that it is doubtful whether the successor arrangement envisaged in the letter of intent (LoI) dated January 14, 2022, can be successfully concluded in the second quarter of 2022 as planned.
Today, the Board of Management has therefore decided to ask the Supervisory Board of RHÖN-KLINIKUM AG as a precautionary measure to approve a termination of the existing agreement of UKGM, the State of Hesse and the universities in Gießen and Marburg from 2017. The termination of the agreement should come into force on December 31, 2022, and would have to be declared in due time by June 30, 2022. The Board of Management feels compelled to take this precautionary step to secure the necessary room for maneuver in the event that the new agreement is not reached in time. The Supervisory Board will decide on the proposed resolution at an extra-ordinary meeting to be convened at short notice.
Regardless, the company remains committed to the contents of the letter of intent dated January 14, 2022, and hopes to conclude a corresponding follow-up agreement by the end of 2022.
09-May-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a.d.Saale
Germany
Phone:
+49 (0)9771 - 65-0
Fax:
+49 (0)9771 - 97 467
E-mail:
rka@rhoen-klinikum-ag.com
Internet:
www.rhoen-klinikum-ag.com
ISIN:
DE0007042301
WKN:
704230
Listed:
Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
Rhoen Klinikum AG is a Germany-based provider of health care services. The Company operates acute hospitals, medical care centers, and rehabilitation hospitals across Germany: six clinics on Campus Bad Neustadt, including the Cardiovascular Clinic, the Frankenklinik for the Rehabilitation of Cardiovascular Patients, the Clinic for Hand Surgery, the Neurological Clinic, the Psychosomatic clinic and the Saaletalklinik with two additional addiction therapy facilities; Klinikum Frankfurt (Oder) comprises clinics, psychiatric outpatient institutions, and day clinics; University Hospital Giessen and Marburg (UKGM) offers medical services, modern diagnostics and comprehensive therapy in various areas, including ophthalmology, trauma surgery and dentistry, and Zentralklinik Bad Berka provides health care services to patients with thoracic, pulmonary and vascular diseases, tumors, neurological conditions, and diseases of the spinal column, joints and heart, among others.
RHÖN-KLINIKUM Aktiengesellschaft: The Board of Management of RHÖN-KLINIKUM AG considers timely agreement with the State of Hesse on granting subsidies to UKGM to be questionable